ES2195112T3 - Procedimiento para la preparacion de acido purificado y su utilizacion. - Google Patents

Procedimiento para la preparacion de acido purificado y su utilizacion.

Info

Publication number
ES2195112T3
ES2195112T3 ES97901080T ES97901080T ES2195112T3 ES 2195112 T3 ES2195112 T3 ES 2195112T3 ES 97901080 T ES97901080 T ES 97901080T ES 97901080 T ES97901080 T ES 97901080T ES 2195112 T3 ES2195112 T3 ES 2195112T3
Authority
ES
Spain
Prior art keywords
preparation
procedure
purified acid
protein
content
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97901080T
Other languages
English (en)
Other versions
ES2195112T5 (es
Inventor
Wolfgang Kuhne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8222465&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2195112(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Roche Diagnostics GmbH filed Critical Roche Diagnostics GmbH
Publication of ES2195112T3 publication Critical patent/ES2195112T3/es
Application granted granted Critical
Publication of ES2195112T5 publication Critical patent/ES2195112T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C07H1/08—Separation; Purification from natural products
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091—Purification or manufacturing processes for gene therapy compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101—Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

LA INVENCION TRATA DE UNA PREPARACION DE ACIDO NUCLEICO CON UN CONTENIDO INFERIOR AL 1 % DE PROTEINA, PREFERENTEMENTE INFERIOR AL 0,1 % DE PROTEINA, LIBRE DE BROMUROS DE ETIDIUM, FENOL, CLORURO DE CESIO Y DETERGENTES BASADOS EN OCTILFENOLPOLI(ETILENGLICOLETER) N , ASI COMO CON UN CONTENIDO INFERIOR A 1 EU/MG ADN DE ENDOTOXINAS. DICHA PREPARACION ES APTA COMO MEDICAMENTO, EN ESPECIAL EN EL CAMPO DE LA TERAPIA GENETICA.
ES97901080.8T 1996-02-06 1997-01-24 Procedimiento para la preparación de ácido nucleico purificado y el uso del mismo Expired - Lifetime ES2195112T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP96101628 1996-02-06
EP96101628 1996-02-06
PCT/EP1997/000321 WO1997029113A2 (de) 1996-02-06 1997-01-24 Verfahren zur herstellung von gereinigter nukleinsäure und deren verwendung

Publications (2)

Publication Number Publication Date
ES2195112T3 true ES2195112T3 (es) 2003-12-01
ES2195112T5 ES2195112T5 (es) 2015-10-15

Family

ID=8222465

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97901080.8T Expired - Lifetime ES2195112T5 (es) 1996-02-06 1997-01-24 Procedimiento para la preparación de ácido nucleico purificado y el uso del mismo

Country Status (12)

Country Link
US (8) US6750333B1 (es)
EP (1) EP0880536B2 (es)
JP (1) JP3442788B2 (es)
KR (1) KR100318808B1 (es)
CN (1) CN1121408C (es)
AT (1) ATE238321T1 (es)
AU (1) AU1444997A (es)
CA (1) CA2245576C (es)
DE (1) DE59709915D1 (es)
DK (1) DK0880536T4 (es)
ES (1) ES2195112T5 (es)
WO (1) WO1997029113A2 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746412B1 (fr) 1996-03-21 1998-06-12 Rhone Poulenc Rorer Sa Purification d'adn plasmidique de qualite pharmaceutique
US7026468B2 (en) * 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
DE19859703B4 (de) 1998-12-23 2009-10-29 Macherey, Nagel Gmbh & Co. Handelsgesellschaft Verfahren zur Aufreinigung von Nukleinsäuren sowie Anionenaustauscher zur Durchführung dieses Verfahrens
DE19903507A1 (de) 1999-01-29 2000-08-10 Roche Diagnostics Gmbh Verfahren zur Herstellung endotoxinfreier oder an Endotoxin abgereicherter Nukleinsäuren und deren Verwendung
DE50008101D1 (de) * 2000-02-16 2004-11-11 Macherey Nagel Gmbh & Co Hg Verfahren zur Aufreinigung von Nukleinsäuren sowie Anionenaustauscher zur Durchführung dieses Verfahrens
KR100356738B1 (ko) * 2000-09-07 2002-10-18 주식회사 삼양제넥스 염기성 단백질로부터 엔도톡신을 제거하는 방법
GB0028361D0 (en) * 2000-11-21 2001-01-03 Glaxo Group Ltd Method of separating extra chromosomal dna from other cellular components
GB0217963D0 (en) * 2002-08-02 2002-09-11 Cyclops Genome Sciences Ltd Purification of nucleic acids
DE10238630A1 (de) * 2002-08-19 2004-03-04 Macherey, Nagel Gmbh & Co. Handelsgesellschaft Verfahren zur Isolierung biologischer Makromoleküle sowie Vorrichtung zur Durchführung dieses Verfahrens
CA2498518A1 (en) * 2002-09-13 2004-03-25 Valentis, Inc. Apparatus and method for preparative scale purification of nucleic acids
JP5173406B2 (ja) * 2004-04-02 2013-04-03 ネクストテツク・ゲー・エム・ベー・ハー 生体高分子のクロマトグラフ分離のための複合吸収剤材料の製造方法
DK2027272T3 (en) * 2006-05-24 2016-03-14 Scarab Genomics Llc Plasmid DNA PREPARATIONS AND METHODS FOR THE MANUFACTURE OF SAME
EP2275431A3 (en) * 2008-01-18 2011-05-25 Bio-Rad Laboratories, Inc. Enhanced fractionation of phosphorylated and nonphosphorylated biomolecules by apatite chromotography
CA2739341A1 (en) * 2008-04-30 2009-11-05 Strike Bio, Inc. Highly pure plasmid dna preparations and processes for preparing the same
US8822672B2 (en) 2009-05-26 2014-09-02 Eurogentec S.A. Method and device for producing and/or purifying polynucleotides and products obtainable thereof
MX346115B (es) * 2009-08-06 2017-03-08 Genentech Inc * Metodo para mejorar la eliminación de virus en la purificacion proteica.
CN108148831A (zh) * 2018-01-15 2018-06-12 南京驯鹿医疗技术有限公司 一种无内毒素质粒大量制备工艺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3639949A1 (de) 1986-11-22 1988-06-09 Diagen Inst Molekularbio Verfahren zur trennung von langkettigen nukleinsaeuren
JPH01135792A (ja) 1987-11-20 1989-05-29 Mitsui Toatsu Chem Inc 核酸の分離・精製方法
US5561064A (en) * 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
US5990301A (en) * 1994-02-07 1999-11-23 Qiagen Gmbh Process for the separation and purification of nucleic acids from biological sources
ATE187733T1 (de) * 1994-02-07 2000-01-15 Qiagen Gmbh Verfahren zur herstellung endotoxinfreier oder an endotoxin abgereicherter nucleinsäuren und/oder oligonucleotide für die gentherapie
CA2192342A1 (en) 1994-07-15 1996-02-01 Ann L. Lee A method for large scale plasmid purification
US5576196A (en) 1995-01-13 1996-11-19 Vical Incorporated Process for reducing RNA concentration in a mixture of biological material using diatomaceous earth
US6214586B1 (en) * 1997-12-08 2001-04-10 Genzyme Corporation Method for purifying plasmid DNA and plasmid DNA substantially free of genomic DNA
US6759394B2 (en) * 2001-07-26 2004-07-06 Board Of Supervisors Of La. State Un. & Agricultural And Mechanical College Cancer gene therapy based on translational control of a suicide gene

Also Published As

Publication number Publication date
KR19990082308A (ko) 1999-11-25
EP0880536B1 (de) 2003-04-23
JPH11509554A (ja) 1999-08-24
CN1121408C (zh) 2003-09-17
WO1997029113A2 (de) 1997-08-14
US9421279B2 (en) 2016-08-23
US20130315985A1 (en) 2013-11-28
US20060165660A1 (en) 2006-07-27
DE59709915D1 (de) 2003-05-28
WO1997029113A3 (de) 1997-10-02
ATE238321T1 (de) 2003-05-15
JP3442788B2 (ja) 2003-09-02
US20040209835A1 (en) 2004-10-21
US20140287026A1 (en) 2014-09-25
CA2245576C (en) 2004-03-23
EP0880536A2 (de) 1998-12-02
US6750333B1 (en) 2004-06-15
US20130004562A1 (en) 2013-01-03
US20100074946A1 (en) 2010-03-25
ES2195112T5 (es) 2015-10-15
DK0880536T3 (da) 2003-08-11
US20110293708A1 (en) 2011-12-01
KR100318808B1 (ko) 2004-05-20
EP0880536B2 (de) 2015-08-05
DK0880536T4 (en) 2015-09-07
CA2245576A1 (en) 1997-08-14
CN1210541A (zh) 1999-03-10
AU1444997A (en) 1997-08-28

Similar Documents

Publication Publication Date Title
ES2195112T3 (es) Procedimiento para la preparacion de acido purificado y su utilizacion.
Lee et al. Effects of a hexameric deoxyriboguanosine run conjugation into CpG oligodeoxynucleotides on their immunostimulatory potentials
DE69632536D1 (de) Impfstoffe für das respiratorische-synzytial-virus mit nuklein säuren
IT1206311B (it) Agente terapeutico a base di oligonucleotide e metodi per laproduzione dello stesso.
MA26466A1 (fr) Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation .
PL350658A1 (en) Medical preparations for the treatment of alpha−galactosidase a deficiency
FI962799A0 (fi) Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
BR9205640A (pt) Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares
DE69730218D1 (de) Fusogene liposomen
AR020048A1 (es) Un polipeptido dependiente de la vitamina k, una composicion farmaceutica que lo comprende, el uso del mismo para la manufactura de un medicamento, unacido nucleico aislado que codifica a dicho polipeptido y una celula hospedante de mamifero.
ITRM920590A0 (it) Sistema per la realizzazione distrutture in fibra di carbonio, e procedimento per detto, particolarmente idoneo per applicazioni aeronautiche.
BR9712138A (pt) Vìrus de rna isolado, vacina, processo para imunizr um indivìduo para induzir proteção contra um vìrus de rna não segmentado, sentido negativo, de filamento único, da ordem mononegavirales e para produzir vìrus de rna, molécula de ácido nucleico isolada e composição.
BR9610511B1 (pt) construções de dna, úteis em terapia genética, compreendendo ao menos uma sequência nucléica de interesse e composição farmacêutica.
DE3781005D1 (de) Adsorptionsmittel fuer chromatographie, methode zur herstellung desselben und saeulensystem fuer chromatographie.
BR0114199A (pt) Sequências de nucleotìdeos que medeiam a fertilidade masculina e métodos de uso das mesmas
AU7247891A (en) Purified myeloblastin, nucleic acid molecule encoding same, and uses thereof
DK0678097T3 (da) Hidtil ukendte colon- eller ileumspecifikke steroidderivater
AU6745287A (en) Dna sequences coding for proteins having the biological activity of husi-type i inhibitors, biotechnological methods for the preparation of said proteins and pharmaceutical compositions containing said proteins
ES2146214T3 (es) Vacunas para actinobacillus pleuropneumoniae.
DE3789673D1 (de) Selbstansaugendes Zufuhrsystem zur Verabreichung eines Heilmittels.
WO1998006841A3 (en) Two human nsp-like proteins
AR033340A1 (es) Factor activador de la citoquina altamente purificado y metodos de uso
FI972170A0 (fi) Peptidejä, jotka kykenevät sitoutumaan GAP-proteiinin SH3-domeeniin, näitä peptidejä koodittavia nukleotidisekvenssejä, niiden valmistus ja käyttö
BR9815496A (pt) Vacinas de ácido nucléico que codificam proteìna gde vìrus sincicial respiratório
IT8919696A0 (it) Sistema di profilati, per la realizzazione di serramenti in genere.